Evidence map›Paper›PMID 30717826›Full record

ArticleeLife2019

HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses.

Simon Langer, Christian Hammer, Kristina Hopfensperger, Lukas Klein, Dominik Hotter, Paul D De Jesus, Kristina M Herbert, Lars Pache, Nikaïa Smith, Johannes A van der Merwe and 4 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. The HIV-1 Vpr R77Q mutant alters host apoptotic gene regulation in CD4+ T cells.Frontiers in cellular and infection microbiology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Simon Langer *Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Christian Hammer *School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID 0000-0003-4548-7548
Kristina Hopfensperger *Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Lukas KleinInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Dominik HotterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Paul D De JesusInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States.
Kristina M HerbertInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States.
Lars PacheInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States.
Nikaïa SmithInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0002-0202-612X
Johannes A van der MerweInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Sumit K ChandaInfectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States.
Jacques FellaySchool of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID 0000-0002-8240-939X
Frank KirchhoffInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
Daniel SauterInstitute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.ORCID 0000-0001-7665-0040
Universität Ulm · DESanford Burnham Prebys Medical Discovery Institute · USSIB Swiss Institute of Bioinformatics · CH

Funding

Deutsche Forschungsgemeinschaft 404687549Deutsche Forschungsgemeinschaft SPP 1923
6 · The paper itself

Abstract

Many viral pathogens target innate sensing cascades and/or cellular transcription factors to suppress antiviral immune responses. Here, we show that the accessory viral protein U (Vpu) of HIV-1 exerts broad immunosuppressive effects by inhibiting activation of the transcription factor NF-κB. Global transcriptional profiling of infected CD4 +T cells revealed that

Indexed as

Host-Pathogen InteractionsImmune EvasionImmunity, InnateCD4-Positive T-LymphocytesCells, CulturedDown-RegulationHIV-1Human Immunodeficiency Virus ProteinsHumansNF-kappa BTranscription, GeneticViral Regulatory and Accessory ProteinsViroporin ProteinsHuman Immunodeficiency Virus ProteinsNF-kappa BViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1HIV-1humanimmune activationimmunologyinfectious diseaseinflammationmicrobiologyNF-κBRNA-SeqtetherinvirusVpu

Identifiers

PMID30717826
PMCPMC6372280
OpenAlexW2911458485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.